Collection of biospecimens from cancer patients for biomarker analysis
The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit/Resistance to Cancer Therapeutics.
This study is collecting samples from cancer patients to see how their biology affects treatment outcomes and to improve our understanding of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Baylor Research Institute Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 8 sites (College Station, Texas and 7 other locations) |
| Trial ID | NCT05371756 on ClinicalTrials.gov |
What this trial studies
The Texas Immuno-Oncology Biorepository (TIOB) aims to collect and store a variety of biospecimens, including tissue, blood, urine, and stool, from cancer patients undergoing standard surgical interventions or FDA-approved immunotherapies. This observational study will gather comprehensive clinical and radiological data from a diverse patient population, allowing for in-depth analysis of immunological and molecular biomarkers. The biorepository will facilitate various studies, including genomic, proteomic, and immune cell analysis, to enhance understanding of cancer biology and treatment outcomes. By integrating multi-omics technologies, the TIOB seeks to uncover complex biological interactions that influence cancer progression and treatment resistance.
Who should consider this trial
Good fit: Ideal candidates include patients suspected of being at risk for cancer or those with confirmed malignancies, including those receiving immunotherapy or surgical interventions.
Not a fit: Patients unwilling to donate blood or provide informed consent for biospecimen collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to improved understanding of cancer biology and more effective treatment strategies for patients.
How similar studies have performed: Other studies utilizing biorepositories for cancer biomarker analysis have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant is over 18 years of age at the time of signing the informed consent form. * Participant is able and willing to sign an informed consent form. * Participant is suspected by a provider of being at risk for developing cancer, OR * Participant has confirmed or clinically suspected malignancy by a provider. This includes but is not limited to: 1. Participants who may be candidates for or are scheduled to receive standard of care immunotherapy treatment for the first time for their current cancer diagnosis, regardless of any prior non-immunotherapy treatment. 2. Participants who are enrolled in a clinical trial to receive an investigational, novel immunotherapy drug for the first time for their current cancer diagnosis. 3. Participants who may be surgical candidates for their current cancer diagnosis, regardless of any prior treatment. Exclusion Criteria: * Participant is unable or unwilling to donate blood. * Concurrent medical or psychiatric condition or disease that may compromise the ability to give documented informed consent, is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
Where this trial is running
College Station, Texas and 7 other locations
- Baylor Scott & White Medical Center - College Station — College Station, Texas, United States (Recruiting)
- Baylor University Medical Center - Dallas — Dallas, Texas, United States (Recruiting)
- Baylor Scott & White All Saints Medical Center - Fort Worth — Fort Worth, Texas, United States (Recruiting)
- Baylor Scott & White Medical Center - Plano — Plano, Texas, United States (Recruiting)
- Baylor Scott & White Medical Center - Round Rock — Round Rock, Texas, United States (Recruiting)
- Baylor Scott & White Medical Center - Temple — Temple, Texas, United States (Recruiting)
- Baylor Scott & White Medical Center - Hillcrest — Waco, Texas, United States (Recruiting)
- Baylor Scott & White Medical Center - Waxahachie — Waxahachie, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Ronan J Kelly, MD, MBA — Baylor Scott & White Research Institute
- Study coordinator: Pukar Ratti, MSChE, MSHCM
- Email: TIOBReferral@BSWHealth.org
- Phone: 214-818-8472
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.